○Taku Ishii1, Susumu Hosokawa2, Naofumi Sumitomo3, Hidekazu Ishida4, Shinichi Takatsuki5, Keiko Uchida6, Hiroyuki Fukushima7, Shigetoyo Kogaki8, Hiroyuki Yamagishi9, Shozaburo Doi10
(1.Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, 2.Department of Pediatricsese Red Cross Musashino Hospital, Tokyo, 3.Department of Pediatrics, Keio University, Tokyo, 4.Department of Pediatrics, Osaka University, Osaka, 5.Department of Pediatrics, Toho University, Tokyo, 6.Department of Physiology, Tokyo Medical University, Tokyo, 7.Department of Pediatrics, Tokyo Dental Colledge Ichikawa General Hospital, Chiba, 8.Department of Pediatrics, Osaka Medical Center, Osaka, 9.Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, 10.Department of Nursing Discipline, Tokyo Health Care University, Tokyo)
Keywords:CHD-PAH, pharmacological treatment, efficacy
抄録パスワード認証パスワードは「2024年 ニュースレター No.2(冊子のみ)、会員への配信メール」に記載されています。